Pulmatrix and Cullgen are pursuing a merger, supporting each other while exploring alternatives, seeking approval from China Securities Regulatory Commission.
Pulmatrix, headquartered in FRAMINGHAM, Mass., is showing ongoing support for Cullgen in their efforts to gain approval for their merger from the China Securities Regulatory Commission. The merger involves Pulmatrix, Inc. (Nasdaq: PULM), a biopharmaceutical firm that concentrates on specialized drug delivery platforms. The collaboration aims to combine resources, with significant financial implications as highlighted by the stock exchange listing on Nasdaq.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments